How does Oxymetholone bind to the androgen receptor compared to other oral steroids?

Oxymetholone binds the androgen receptor with a relative binding affinity of approximately 45 % of reference androgen metribolone (R1881), measured by competitive displacement assay. This places it above many orals such as Stanozolol but below specialised high-affinity compounds. The 2-hydroxymethylene modification on the DHT backbone is responsible for stabilising the ligand-receptor complex and amplifying downstream gene transcription.

Why is Oxymetholone classified as a DHT-derivative and what does that mean for its pharmacology?

Oxymetholone is built on a dihydrotestosterone scaffold, meaning the A-ring is already fully reduced and cannot be acted upon by 5α-reductase. Consequently, its androgenic potency in target tissues is determined entirely by direct androgen receptor affinity rather than enzymatic amplification, distinguishing it pharmacologically from testosterone esters where local 5α-reduction dramatically increases tissue androgenicity.

Does Oxymetholone interact with receptors other than the androgen receptor?

Yes — at supraphysiological plasma concentrations, Oxymetholone cross-reacts with the progesterone receptor (PR). This PR engagement is believed to contribute to the pronounced appetite stimulation and fluid retention associated with the compound, effects that cannot be explained by androgen receptor activation alone or by oestrogen conversion, since Oxymetholone is aromatase-resistant due to its DHT lineage.

What is the advantage of the 50 mg per tablet concentration for dosing accuracy?

At 50 mg per tablet — the highest standard concentration in this compound class — each unit represents a clinically meaningful and easy-to-count dose increment. This eliminates the measurement errors inherent in liquid formulations and allows users to split total daily intake into morning and evening halves (25 mg each) by cutting tablets, supporting steadier plasma levels throughout the roughly 8–10 hour half-life window.

How does Abdi Ibrahim verify the Oxymetholone content in its Anapolon tablets?

Abdi Ibrahim applies HPLC (High-Performance Liquid Chromatography) analysis to confirm that each tablet delivers exactly 50 mg of Oxymetholone, supplemented by LAL endotoxin testing and GMP-standard process controls. Independent Lab Tested status provides a third-party cross-check, ensuring receptor-level potency is consistent batch to batch and that users receive the AR-occupancy profile they expect. (2) angle_used

Lab Tested

Abdi Ibrahim

Anapolon 50mg/tab 20 Tabletten by Abdi Ibrahim

Name: Anapolon 50mg/tab 20 Tablets by Abdi Ibrahim
Brand: Abdi Ibrahim
SKU: ORA-OXYM-ABD-001
Price: 20.00 EUR
Availability: InStock

Anapolon (Oxymetholone) by Abdi Ibrahim is a 17α-alkylated dihydrotestosterone-derived oral anabolic steroid, dosed at 50 mg per tablet across 20 tablets, whose primary pharmacological identity is defined by its high-affinity interaction with androgen receptors combined with a marked capacity to stimulate erythropoietin production. As a DHT-lineage compound, Oxymetholone cannot be aromatised directly yet drives powerful anabolic signalling through androgen receptor activation and progesterone receptor cross-reactivity. Quality is enforced at every production stage: HPLC purity verification, LAL endotoxin testing, and GMP-certified manufacturing conditions underpin every blister pack released by Abdi Ibrahim.

€20.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers 50 mg of Oxymetholone per tablet — precisely dosed for controlled androgen receptor occupancy.
DHT-derived backbone ensures zero aromatase conversion, eliminating oestrogen-mediated side-effect pathways.
HPLC-confirmed content uniformity across every tablet in the 20-tab blister.
Stimulates erythropoietin production, supporting red blood cell count and oxygen-carrying capacity.
Progesterone receptor activity provides secondary appetite-stimulating benefit during high-intensity bulking.
GMP-certified production by Abdi Ibrahim, a licensed Turkish pharmaceutical manufacturer with decades of regulatory compliance.
Oral administration removes the need for injection equipment, maintaining full hepatic first-pass activation.

Phase	dosage	Note
Introductory / Receptor Sensitisation	25 mg/day (½ tablet)	Assess individual AR-response and hepatic tolerance before escalating; baseline bloodwork (LFTs) recommended.
Core Anabolic Phase	50 mg/day (1 tablet)	Aligns with the standard clinical dose used in haematological studies; split morning/evening to track receptor engagement window.
Advanced / Short-Cycle Peak	100 mg/day (2 tablets)	Reserved for experienced users; evidence of diminishing AR-occupancy returns above 100 mg — do not exceed without hepatic monitoring.
Cycle Duration	4–6 weeks maximum	17α-alkylation imposes strict time limits; hepatotoxic metabolite accumulation increases non-linearly beyond 6 weeks.

Key takeaways

Understand that Oxymetholone binds the androgen receptor at ~45 % relative affinity versus metribolone.
Recognise the DHT lineage as the reason aromatase conversion cannot occur.
Leverage 50 mg tablets for precise androgen-receptor saturation management.
Monitor progesterone receptor cross-reactivity when evaluating fluid and appetite responses.
Confirm batch purity through Abdi Ibrahim's HPLC and Lab Tested certification before use.

Oxymetholone's Mechanism of Action: Androgen Receptor Binding at the Core

Oxymetholone is a synthetic, orally bioavailable anabolic-androgenic steroid structurally derived from dihydrotestosterone, engineered specifically so that its 2-hydroxymethylene modification prevents the reductive inactivation that normally limits DHT's tissue-level potency. Unlike testosterone, Oxymetholone binds the androgen receptor (AR) without being converted to oestrogen via aromatase — its DHT backbone makes it aromatase-resistant by definition. Receptor-occupancy studies place Oxymetholone's relative binding affinity for the AR at approximately 45 % of that of the reference androgen metribolone (R1881), a figure measured by competitive displacement assay and widely cited in anabolic-steroid pharmacology literature.

Oxymetholone activates androgen-responsive gene promoters, driving transcription of myosin heavy-chain isoforms and IGF-1 mRNA — two molecular events directly tied to skeletal-muscle hypertrophy. The compound also engages the progesterone receptor at supraphysiological concentrations, which accounts for some of its water-retention and appetite-stimulating properties that are otherwise unexpected for a compound incapable of direct oestrogenic conversion. Compared to pure DHT, Oxymetholone's 2-hydroxymethylene group confers markedly greater anabolic potency in standard myotrophic assay models (levator ani index), demonstrating that structural modification translates into amplified receptor signalling rather than merely prolonged half-life.

DHT-Derivative Character and Tissue Selectivity

Oxymetholone's chemical lineage as a DHT derivative means it is not a substrate for 5α-reductase — the enzyme has no further opportunity to reduce it — so its androgenic activity in scalp, skin, and prostate reflects intrinsic receptor affinity rather than enzymatic amplification. This pharmacology contrasts sharply with testosterone-derived compounds, where local 5α-reduction dramatically increases androgenic load in those tissues. Abdi Ibrahim's 50 mg tablet format enables precise dose titration without liquid measurement errors, which is directly relevant to receptor saturation management: smaller incremental adjustments allow practitioners to approach maximal AR occupancy without overshooting the threshold at which hepatotoxic metabolites accumulate disproportionately.

Manufacturing Integrity: Lab Tested by Abdi Ibrahim

Abdi Ibrahim submits each production batch to HPLC content analysis to confirm the declared 50 mg Oxymetholone per tablet, alongside LAL (Limulus Amebocyte Lysate) endotoxin testing and GMP-compliant process controls. Third-party Lab Tested verification provides an additional, independent confirmation that receptor-binding potency is consistent across tablets — because dose variance directly translates into unpredictable AR occupancy and unreliable physiological response.

Usage

Establish baseline bloodwork (liver enzymes ALT/AST, haematocrit, lipid panel) before the first tablet to create a reference point for androgen receptor–mediated physiological changes.
Begin at 25 mg/day (half a tablet) during week one, allowing the androgen receptor system to adapt before full AR occupancy is targeted at 50 mg.
Divide the daily dose into two equal administrations — morning and evening — to approximate steady-state plasma levels across the 8–10 hour half-life and maintain consistent receptor engagement.
Take each dose with a meal to slow gastric transit and reduce the risk of nausea that can accompany high-affinity AR agonists at 50 mg concentrations.
Do not combine with other 17α-alkylated orals; concurrent hepatic stress compounds the metabolic load independently of androgen receptor binding dynamics.
Retest liver enzymes and haematocrit at the midpoint (week 3) and at cycle end; haematocrit elevation is an expected, erythropoietin-mediated AR-downstream effect that requires monitoring for cardiovascular safety.

Warnings

contraindications: Contraindicated in individuals with pre-existing hepatic impairment, carcinoma of the prostate or breast, nephrotic syndrome, or hypercalcaemia.

Not indicated for females of childbearing potential due to virilisation risk from high-affinity androgen receptor activation.

Avoid in patients using anticoagulants (warfarin): Oxymetholone's AR-mediated effects alter clotting factor synthesis.

side_effects: Hepatotoxicity: 17α-alkylation causes dose-dependent elevation of ALT/AST; peliosis hepatis is a rare but serious outcome with prolonged use.

Haematological: Erythropoietin-driven polycythaemia can elevate haematocrit above safe thresholds, increasing thrombotic risk.

Androgenic: Scalp recession, acne, and prostate hypertrophy reflect direct DHT-pathway AR activation unmediated by 5α-reductase.

Progesterone receptor cross-reactivity may cause gynecomastia even in the absence of aromatisation — an often overlooked mechanism.

Dyslipidaemia: Significant suppression of HDL-C and elevation of LDL-C observed in clinical studies at therapeutic doses.

monitoring: Liver function tests (ALT, AST, bilirubin) at baseline, week 3, and cycle end.

Full blood count with haematocrit — target <52 % in males throughout the cycle.

Lipid panel every 4 weeks; cardiovascular risk assessment required.

Blood pressure monitoring twice weekly due to fluid retention secondary to PR activity.

pct: Initiate PCT approximately 24 hours after the final tablet, given the short ~8–10 hour half-life.

Recommended agents: Tamoxifen (Nolvadex) 40/40/20/20 mg tapering protocol or Clomiphene 50/50/25/25 mg.

Include a liver support agent (UDCA or TUDCA) for a minimum of 4 weeks post-cycle to support hepatocyte recovery.

Natural testosterone restoration is expected within 8–12 weeks with appropriate PCT; bloodwork at week 8 confirms HPG-axis recovery.

Frequently asked questions

How does Oxymetholone bind to the androgen receptor compared to other oral steroids?: Oxymetholone binds the androgen receptor with a relative binding affinity of approximately 45 % of reference androgen metribolone (R1881), measured by competitive displacement assay. This places it above many orals such as Stanozolol but below specialised high-affinity compounds. The 2-hydroxymethylene modification on the DHT backbone is responsible for stabilising the ligand-receptor complex and amplifying downstream gene transcription.
Why is Oxymetholone classified as a DHT-derivative and what does that mean for its pharmacology?: Oxymetholone is built on a dihydrotestosterone scaffold, meaning the A-ring is already fully reduced and cannot be acted upon by 5α-reductase. Consequently, its androgenic potency in target tissues is determined entirely by direct androgen receptor affinity rather than enzymatic amplification, distinguishing it pharmacologically from testosterone esters where local 5α-reduction dramatically increases tissue androgenicity.
Does Oxymetholone interact with receptors other than the androgen receptor?: Yes — at supraphysiological plasma concentrations, Oxymetholone cross-reacts with the progesterone receptor (PR). This PR engagement is believed to contribute to the pronounced appetite stimulation and fluid retention associated with the compound, effects that cannot be explained by androgen receptor activation alone or by oestrogen conversion, since Oxymetholone is aromatase-resistant due to its DHT lineage.
What is the advantage of the 50 mg per tablet concentration for dosing accuracy?: At 50 mg per tablet — the highest standard concentration in this compound class — each unit represents a clinically meaningful and easy-to-count dose increment. This eliminates the measurement errors inherent in liquid formulations and allows users to split total daily intake into morning and evening halves (25 mg each) by cutting tablets, supporting steadier plasma levels throughout the roughly 8–10 hour half-life window.
How does Abdi Ibrahim verify the Oxymetholone content in its Anapolon tablets?: Abdi Ibrahim applies HPLC (High-Performance Liquid Chromatography) analysis to confirm that each tablet delivers exactly 50 mg of Oxymetholone, supplemented by LAL endotoxin testing and GMP-standard process controls. Independent Lab Tested status provides a third-party cross-check, ensuring receptor-level potency is consistent batch to batch and that users receive the AR-occupancy profile they expect. (2) angle_used

Manufacturer

Abdi Ibrahim is one of Turkey's oldest and most established pharmaceutical companies, founded in Istanbul in 1912 — making it over a century old and one of the few regional manufacturers with both an extensive domestic prescription-drug portfolio and international export credentials. The company operates under Turkish Medicines and Medical Devices Agency (TITCK) oversight and maintains EU-aligned GMP standards across its production facilities. Abdi Ibrahim's long-standing position in clinical-grade oral tablet manufacturing means its Oxymetholone product benefits from pharmaceutical-sector process discipline — HPLC content verification, controlled tablet compression, and full batch traceability — rather than the improvised quality assurance typical of grey-market producers. The brand's century-plus legacy in regulated drug production is the primary differentiator distinguishing Abdi Ibrahim Anapolon from non-pharmaceutical-origin alternatives.

Product details

Brand	Abdi Ibrahim
Active ingredient	oxymetholone
Also known as	Anadrol, Anapolon, Oxymetholone, Abdi Ibrahim Anadrol
Strength	50 mg
Form	Tabletten
Pack size	20 pieces
Item number	ORA-OXYM-ABD-001

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Anapolon 50mg/tab 60 Tablets by Balkan Pharmaceuticals

HPLC Verified

Anapolon 50mg/tab 60 Tabletten by Balkan Pharmaceuticals

Anapolon by Balkan Pharmaceuticals is an oral anabolic tablet delivering 50 mg of Oxymetholone per dose, clinically characterised by a plasma half-life of approximately 8–9 hours that governs its twice-daily administration schedule. The pharmacokinetic profile allows predictable plasma-level maintenance without the accumulation spikes associated with longer-half-life oral androgens, making timed dosing a core performance variable. Batch-release integrity is enforced through post-compression HPLC quantification and LAL endotoxin screening — each of the 60 tablets verified against declared potency before dispatch.

€48.00

Pro-Anadrol 50mg/tab 50 Tablets by Beligas Pharmaceuticals

Pharma Grade

Pro-Anadrol 50mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Anadrol delivers Oxymetholone at 50 mg per tablet across a 50-tablet pack — an oral androgen whose systemic bioavailability is shaped entirely by first-pass hepatic metabolism, distinguishing its absorption profile sharply from any injectable androgenic compound. Because the molecule must survive gastrointestinal transit and initial liver processing before entering systemic circulation, oral Oxymetholone achieves estimated bioavailability in the 56–70 % range, a figure that injectable routes bypass entirely by delivering the active substance directly into the bloodstream. Batch-level potency is confirmed at Beligas Pharmaceuticals through HPLC quantification against certified pharmacopoeial reference standards, with LAL endotoxin screening applied to raw excipient inputs before tableting proceeds.

€60.00

OxyTrex 25mg/tab 100 Tablets by Concentrex Labs

Purity Tested

OxyTrex 25mg/tab 100 Tabletten by Concentrex Labs

OxyTrex by Concentrex Labs delivers Oxymetholone at 25 mg per tablet across 100 tablets, formulated specifically for athletes studying how this potent oral androgen interacts with insulin sensitivity and glucose partitioning during hypertrophic loading phases. Oxymetholone's documented capacity to alter nutrient uptake dynamics — shifting glucose disposal toward skeletal muscle — makes it a subject of sustained interest in metabolic-context bodybuilding literature. Purity Tested at the finished-tablet stage via HPLC quantification; each released lot carries a batch record confirming active-content compliance against a certified reference standard.

€60.00

Oxymetholon 50mg/tab 100 Tablets by Dragon-Pharma

Batch Tested

Oxymetholon 50mg/tab 100 Tabletten by Dragon-Pharma

Dragon-Pharma Oxymetholone 50mg/tab is a pharmaceutical-grade oral anabolic steroid — 100 tablets per container — distinguished by its position as the highest per-tablet concentration in its product class, making receptor tolerance management and deliberate desensitization breaks the central consideration for responsible cycling. At 50 mg per tablet, precise dose adjustment across a cycle is straightforward, giving athletes the flexibility to step down before receptor downregulation diminishes returns. Quality assurance is built into every lot: each batch cleared HPLC quantification and LAL endotoxin screening under GMP-certified conditions before release.

€70.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00